CN Patent

CN114874189B — 取代的杂芳基衍生物及其组合物及用途

Assigned to Shenzhen Targetrx Inc · Expires 2023-09-29 · 3y expired

What this patent protects

本发明提供了一种取代的杂芳基衍生物及包含该化合物的组合物及其用途，所述的取代的杂芳基衍生物为式(I)所示化合物或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂合物。本发明化合物及其组合物可用于治疗和/或预防野生的和/或突变的EGFR和/或HER2激酶介导的肿瘤。

USPTO Abstract

本发明提供了一种取代的杂芳基衍生物及包含该化合物的组合物及其用途，所述的取代的杂芳基衍生物为式(I)所示化合物或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂合物。本发明化合物及其组合物可用于治疗和/或预防野生的和/或突变的EGFR和/或HER2激酶介导的肿瘤。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN114874189B
Jurisdiction: CN
Classification: —
Expires: 2023-09-29
Drug substance claim: No
Drug product claim: No
Assignee: Shenzhen Targetrx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.